Pediatrix Medical Group, Inc. (MD) Earnings

Management highlights

- Financial Position & Capital Allocation * Reported a solid Q2 2026 in line with internal expectations, with a strong balance sheet supporting practice investments, quality programs, research and growth initiatives * Repurchased just under 2 million shares in Q2 2026, bringing total buybacks since August 2025 to 7 million shares; total shares outstanding fell to 81 million from 87 million at the end of Q2 2025 * The company will continue share repurchases unless attractive acquisition or growth opportunities emerge that meet its operating and financial criteria - Strategic Position & Growth Initiatives * The company holds a sector-leading market footprint in neonatology and maternal-fetal medicine (MFM), with over 170 MFM clinicians across multiple states and services in more than 360 NICUs across 32 states, the largest footprint in the U.S. focused on high-acuity patients * Management is building a nationwide telemedicine offering to augment existing in-person services, pursuing a hybrid tele-in-person model that management believes is superior to standalone telemedicine; the hybrid strategy covers multiple service lines including MFM, neonatology, retinopathy, neurology, and infectious disease * The company is expanding its OBH footprint leveraging existing embedded relationships with over 400 hospital partners, and has recruited dedicated leadership for both hybrid telemedicine and OBH expansion * Management is actively evaluating growth opportunities in women's and children's care, and is open to partnering with third-party joint venture and capital investors to pursue larger opportunities - Operational Performance * Same-unit revenue growth was driven by strong revenue cycle management (RCM) collections, favorable payer mix improvement, and rising patient acuity; payer mix improved 135 basis points year-over-year and 120 basis points sequentially from Q1 2026 * Same-unit patient volumes saw a 2% year-over-year decline, driven primarily by hospital-based neonatology services (NICU days down 3%), which management notes aligns with seasonal trends and a tough year-over-year comparison * Accounts receivable DSO stood at 42.5 days at the end of Q2, down nearly 4 days year-over-year due to improved collections * Salary expense growth has remained stable in a tight range consistent with the past 18 months, with tight internal controls keeping wage growth in check

Guidance

- Management reaffirmed full year 2026 adjusted EBITDA guidance of $280 to $300 million * Full year 2026 G&A expense is expected to fall in the $230 to $240 million range, and will likely land at the higher end of this range due to one-time Q2 2026 executive transition costs; G&A will step down in the second half of 2026 after the one-time expense * Adjusted EBITDA is expected to be roughly evenly split between the third and fourth quarters of 2026 (ratable performance in H2 2026) * Management expects full year 2026 patient volumes to be overall flat to slightly down, consistent with current trends * The RCM collections tailwind driving pricing growth is expected to begin dissipating in the second half of 2026 * Management expects continued upward pressure on pricing from rising patient acuity in H2 2026, continuing the multi-year upward trajectory

Segment performance

The transcript does not break out financial performance for discrete product or service segments. It reports consolidated Q2 2026 results: adjusted EBITDA of $76 million, 4% year-over-year consolidated revenue growth, 2% same-unit revenue growth, 4% same-unit pricing growth, and 2% same-unit volume decrease. Operating cash flow for Q2 2026 was $126 million, down from $138 million in the prior year quarter. G&A expense increased year-over-year due to one-time executive transition costs, D&A expense rose to $5.8 million from $5.3 million, and other non-operating expense fell to $2.9 million from $4.9 million. End of period cash balance was $289 million, total debt was $584 million, and net leverage was just above 1x against the midpoint of 2026 adjusted EBITDA guidance.

Risks & headwinds

- Forward-looking statements are inherently uncertain, and actual results may differ materially due to factors outlined in the company's SEC filings, specifically the Risk Factors section * While the company has not experienced the adverse payer mix shifts seen at peer healthcare firms to date, management does not claim to be immune from future shifts, and the future trajectory of payer mix cannot be guaranteed * Patient volumes have declined modestly for multiple quarters, and while management currently attributes this to seasonal trends, the possibility of an ongoing negative volume trend cannot be ruled out * Birth rate trends may impact future neonatology volumes, though the correlation is not perfect due to the company's focus on high-acuity care

Analyst Q&A

• Q: Why has Pediatrics maintained a stable, improving commercial payer mix relative to peer healthcare companies, and do you expect this trend to hold in the second half of 2026? /

  A: Management notes that the company has not experienced the same adverse payer mix impacts as peers to date, with no signs of shift as of the quarter. While the company cannot guarantee future stability, the logical driver of peer weakness (insurance coverage drops after subsidy lapses) has not impacted Pediatrics to date, and there are no current indicators of a coming change. /

• Q: Given multiple quarters of modest volume decline, do you still believe this is not the start of an ongoing negative trend, and what is your full year volume outlook? /

  A: Management expects full year volume to be flat to slightly down, in line with current trends. The recent decline aligns with typical seasonal patterns and tough year-over-year comparisons. While the company cannot predict long-term trends with certainty, the high-acuity focus of its neonatology business and expansion of hybrid telemedicine into underserved care deserts supports the current outlook. /

• Q: Can you break down the contribution of the three drivers of same-unit pricing growth, and update your acquisition activity and outlook? /

  A: The largest driver of pricing growth is RCM collections, followed by payer mix improvement, then rising patient acuity, which together account for 95% of pricing gains this quarter. All prior dispositions are complete, the company sees many attractive acquisition targets with fair pricing in the women's and children's care space, and it has access to third-party capital from interested partners to pursue larger opportunities that meet its operating and financial criteria. /

• Q: What is the current trajectory of wage inflation, and what is expected for the rest of 2026 and into 2027? /

  A: The company has maintained tight controls on salary expense growth for multiple quarters, holding increases in a steady 3% to 3.5% range, down from mid-single digit growth historically. Management does not expect any change to this stable, controlled wage growth trend going forward.